Recent Finacing
Recent Raise
AFYX Therapeutics develops the Rivelin uni‑directional, occlusive, bioadhesive, biodegradable mucosal drug‑delivery patch; its lead candidate Rivelin‑CLO delivers clobetasol for oral lichen planus in Phase 2b.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
